Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
8.26
USD
|
+1.85%
|
|
-6.67%
|
-20.50%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,793
|
2,171
|
763
|
506.3
|
727.3
|
582.9
|
-
|
-
|
Enterprise Value (EV)
1 |
1,494
|
1,929
|
561.2
|
506.3
|
569.8
|
287.2
|
227.9
|
582.9
|
P/E ratio
|
-11.9
x
|
-13.2
x
|
-3.99
x
|
4.14
x
|
-6.04
x
|
-7.35
x
|
-9.07
x
|
-8.91
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
60.7
x
|
55.7
x
|
28.6
x
|
1.23
x
|
9.57
x
|
6.56
x
|
5.2
x
|
4.13
x
|
EV / Revenue
|
50.6
x
|
49.5
x
|
21
x
|
1.23
x
|
7.5
x
|
3.23
x
|
2.03
x
|
4.13
x
|
EV / EBITDA
|
-10.2
x
|
-10.7
x
|
-2.68
x
|
3.68
x
|
-4.46
x
|
-2.52
x
|
-1.88
x
|
-
|
EV / FCF
|
-16.9
x
|
-12.4
x
|
-2.74
x
|
-
|
-4.72
x
|
-3.93
x
|
-2.35
x
|
-
|
FCF Yield
|
-5.9%
|
-8.07%
|
-36.5%
|
-
|
-21.2%
|
-25.4%
|
-42.6%
|
-
|
Price to Book
|
7.32
x
|
5.81
x
|
3.07
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
39,438
|
45,946
|
46,554
|
64,414
|
70,002
|
70,568
|
-
|
-
|
Reference price
2 |
45.46
|
47.26
|
16.39
|
7.860
|
10.39
|
8.260
|
8.260
|
8.260
|
Announcement Date
|
3/2/20
|
2/24/21
|
2/24/22
|
3/7/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
29.54
|
38.95
|
26.68
|
412.5
|
76.01
|
88.9
|
112.2
|
141
|
EBITDA
1 |
-145.9
|
-180
|
-209.1
|
137.8
|
-127.9
|
-113.9
|
-121.2
|
-
|
EBIT
1 |
-150.5
|
-187.5
|
-215.6
|
130.5
|
-138.1
|
-93.23
|
-59.45
|
-22.77
|
Operating Margin
|
-509.52%
|
-481.29%
|
-808.22%
|
31.64%
|
-181.62%
|
-104.87%
|
-52.99%
|
-16.15%
|
Earnings before Tax (EBT)
1 |
-146
|
-180.1
|
-212.4
|
135.2
|
-119.2
|
-81.46
|
-37.98
|
-35.51
|
Net income
1 |
-145.4
|
-180.6
|
-211.8
|
124.3
|
-118.7
|
-65.33
|
-43.71
|
-47.1
|
Net margin
|
-492.27%
|
-463.54%
|
-794.01%
|
30.14%
|
-156.13%
|
-73.49%
|
-38.96%
|
-33.4%
|
EPS
2 |
-3.830
|
-3.580
|
-4.110
|
1.900
|
-1.720
|
-1.124
|
-0.9102
|
-0.9275
|
Free Cash Flow
1 |
-88.18
|
-155.7
|
-204.9
|
-
|
-120.8
|
-73
|
-97
|
-
|
FCF margin
|
-298.45%
|
-399.77%
|
-767.82%
|
-
|
-158.89%
|
-82.12%
|
-86.47%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/20
|
2/24/21
|
2/24/22
|
3/7/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
4.395
|
19.87
|
1.916
|
5.442
|
2.631
|
402.5
|
35.58
|
7.002
|
16.51
|
16.93
|
16.43
|
32.89
|
12.83
|
46.1
|
EBITDA
1 |
-59.55
|
-39.85
|
-70.22
|
-64.29
|
-
|
-
|
-
|
-
|
-
|
-21.21
|
-28.82
|
-28.63
|
-28.44
|
-
|
EBIT
1 |
-60.96
|
-40.85
|
-72.69
|
-65.82
|
-50.36
|
319.4
|
-27.28
|
-54.11
|
-33.24
|
-23.42
|
-23.81
|
-33.43
|
-32.21
|
6.891
|
Operating Margin
|
-1,387.12%
|
-205.58%
|
-3,793.63%
|
-1,209.54%
|
-1,914.03%
|
79.35%
|
-76.68%
|
-772.84%
|
-201.36%
|
-138.37%
|
-144.91%
|
-101.65%
|
-251.06%
|
14.95%
|
Earnings before Tax (EBT)
1 |
-59.82
|
-40.52
|
-72.7
|
-64.63
|
-47.88
|
320.4
|
-22.96
|
-49.5
|
-27.58
|
-19.2
|
-23
|
-26.03
|
-27.94
|
-4.488
|
Net income
1 |
-60.58
|
-39.15
|
-72.62
|
-64.62
|
-47.85
|
309.4
|
-24.35
|
-51.15
|
-28.69
|
-14.48
|
-23.28
|
-0.2258
|
-29.56
|
-12.03
|
Net margin
|
-1,378.36%
|
-197.04%
|
-3,790.45%
|
-1,187.41%
|
-1,818.55%
|
76.88%
|
-68.45%
|
-730.53%
|
-173.8%
|
-85.56%
|
-141.67%
|
-0.69%
|
-230.38%
|
-26.09%
|
EPS
2 |
-1.170
|
-0.7600
|
-1.190
|
-0.9700
|
-0.7200
|
4.650
|
-0.3600
|
-0.7600
|
-0.4100
|
-0.2000
|
-0.3211
|
0.006110
|
-0.4047
|
-0.1611
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/3/21
|
2/24/22
|
5/4/22
|
8/4/22
|
11/8/22
|
3/7/23
|
5/8/23
|
8/10/23
|
11/7/23
|
3/6/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
299
|
242
|
202
|
-
|
158
|
296
|
355
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-88.2
|
-156
|
-205
|
-
|
-121
|
-73
|
-97
|
-
|
ROE (net income / shareholders' equity)
|
-68.3%
|
-55.1%
|
-64.3%
|
-
|
-24.8%
|
-19.3%
|
-38.3%
|
-
|
ROA (Net income/ Total Assets)
|
-47.5%
|
-39.8%
|
-45.7%
|
-
|
-19.3%
|
-13.3%
|
-17.9%
|
-
|
Assets
1 |
306.3
|
453.3
|
463.8
|
-
|
614.8
|
490.8
|
244.8
|
-
|
Book Value Per Share
|
6.210
|
8.140
|
5.340
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-2.150
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
6.32
|
4.31
|
12.4
|
-
|
2.47
|
5.5
|
5.5
|
1
|
Capex / Sales
|
21.4%
|
11.07%
|
46.49%
|
-
|
3.25%
|
6.19%
|
4.9%
|
0.71%
|
Announcement Date
|
3/2/20
|
2/24/21
|
2/24/22
|
3/7/23
|
3/6/24
|
-
|
-
|
-
|
Last Close Price
8.26
USD Average target price
14.17
USD Spread / Average Target +71.51% Consensus |
1st Jan change
|
Capi.
|
---|
| -20.50% | 583M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|